California Pacific Medical Center
- Type
- Teaching hospital
- Where
- SAN FRANCISCO, CA
- Medicare CCN
- 050047
- Received
- $2,572,542 in 190 records, 2021 ($256,182 general, $2,316,360 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 8 | $256,182 |
| 2021 | Research payment | 182 | $2,316,360 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 10 | $1,313,283 | 2021 |
| Edwards Lifesciences Corporation | 47 | $372,052 | 2021 |
| Jenavalve Technology, Inc. | 1 | $242,056 | 2021 |
| E.R. Squibb & Sons, L.L.C. | 11 | $196,043 | 2021 |
| Genentech, Inc. | 38 | $95,940 | 2021 |
| Medtronic, Inc. | 11 | $55,856 | 2021 |
| Intercept Pharmaceuticals, Inc. | 17 | $52,843 | 2021 |
| Partner Therapeutics, Inc. | 3 | $51,051 | 2021 |
| Regeneron Pharmaceuticals, Inc. | 8 | $47,198 | 2021 |
| ModernaTX, Inc. | 5 | $44,678 | 2021 |
| Novocure Inc. | 4 | $26,925 | 2021 |
| PFIZER INC. | 2 | $14,571 | 2021 |
| Alexion Pharmaceuticals, Inc. | 4 | $12,461 | 2021 |
| Sirtex Medical Inc | 5 | $10,755 | 2021 |
| Roche Products Limited | 1 | $10,050 | 2021 |
| F. Hoffmann-La Roche AG | 3 | $5,939 | 2021 |
| ARRAY BIOPHARMA INC | 5 | $5,123 | 2021 |
| SK Life Science, Inc. | 5 | $4,117 | 2021 |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | 1 | $3,450 | 2021 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,500 | 2021 |
| Eli Lilly and Company | 1 | $1,670 | 2021 |
| Chiesi USA, Inc. | 1 | $1,500 | 2021 |
| Amgen Inc. | 1 | $1,360 | 2021 |
| CSL Behring | 1 | $604 | 2021 |
| Johnson & Johnson Health Care Systems Inc. | 2 | $493 | 2021 |
| Bio-Rad Laboratories, Inc. | 1 | $18 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 182 | $2,316,360 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $242,056 |
| Consulting Fee | 2 | $9,950 |
| Long term medical supply or device loan | 1 | $2,164 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,500 |
| Debt forgiveness | 3 | $511 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $448,142 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $145,256 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $53,279 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $38,946 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $21,191 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,592 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2021 |
| 2021-12-22 | Merck Sharp & Dohme LLC | $38,033 | Research payment | Cash or cash equivalent | Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2021 |
| 2021-12-21 | Merck Sharp & Dohme LLC | $28,085 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2021 |
| 2021-12-17 | Merck Sharp & Dohme LLC | $271,089 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2021 |
| 2021-12-16 | Edwards Lifesciences Corporation | $20,603 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-12-16 | Intercept Pharmaceuticals, Inc. | $8,833 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-16 | Medtronic, Inc. | $888 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-12-15 | Medtronic, Inc. | $16,500 | Research payment | Cash or cash equivalent | Tricuspid 35 Fr TF EFS | 2021 | |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-12-09 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-12-09 | Intercept Pharmaceuticals, Inc. | $395 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $7,587 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-12-06 | Edwards Lifesciences Corporation | $1,550 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-12-03 | Regeneron Pharmaceuticals, Inc. | $15,244 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-12-03 | Regeneron Pharmaceuticals, Inc. | $7,155 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-12-03 | Genentech, Inc. | $1,701 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-12-02 | Regeneron Pharmaceuticals, Inc. | $1,400 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-12-01 | Medtronic, Inc. | $650 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-11-26 | ARRAY BIOPHARMA INC | $2,000 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2021 |
| 2021-11-26 | ARRAY BIOPHARMA INC | $650 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2021 |
| 2021-11-26 | ARRAY BIOPHARMA INC | $573 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2021 |
| 2021-11-26 | Edwards Lifesciences Corporation | $364 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-11-24 | Regeneron Pharmaceuticals, Inc. | $10,349 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-11-19 | Edwards Lifesciences Corporation | $5,625 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-19 | Edwards Lifesciences Corporation | $4,325 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-19 | Genentech, Inc. | $656 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2021 |
| 2021-11-10 | PFIZER INC. | $9,216 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2021 |
| 2021-11-05 | ModernaTX, Inc. | $22,805 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2021 | |
| 2021-11-04 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2021 |
| 2021-11-04 | Edwards Lifesciences Corporation | $2,200 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-11-04 | Edwards Lifesciences Corporation | $1,950 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-11-03 | ModernaTX, Inc. | $394 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2021 | |
| 2021-10-28 | Edwards Lifesciences Corporation | $2,775 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-10-26 | Partner Therapeutics, Inc. | $39,501 | Research payment | Cash or cash equivalent | LEUKINE Drug, Hematology/Oncology | iLEUK Pulm | 2021 |
| 2021-10-26 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-10-22 | Partner Therapeutics, Inc. | $1,500 | Research payment | Cash or cash equivalent | LEUKINE Drug, Hematology/Oncology | iLEUK Pulm | 2021 |
| 2021-10-18 | Edwards Lifesciences Corporation | $7,292 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-10-18 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-10-14 | Edwards Lifesciences Corporation | $5,288 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-10-14 | Alexion Pharmaceuticals, Inc. | $3,925 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 | |
| 2021-10-14 | Alexion Pharmaceuticals, Inc. | $3,700 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 | |
| 2021-10-14 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | EVOQUE TR 2019-06 | 2021 | |
| 2021-10-14 | Edwards Lifesciences Corporation | $337 | Research payment | Cash or cash equivalent | EVOQUE TR 2019-06 | 2021 | |
| 2021-10-13 | ModernaTX, Inc. | $20,478 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2021 | |
| 2021-10-05 | Genentech, Inc. | $1,950 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-09-29 | Intercept Pharmaceuticals, Inc. | $4,480 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-09-29 | Intercept Pharmaceuticals, Inc. | $220 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-09-27 | Roche Products Limited | $10,050 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 2021 |
| 2021-09-27 | F. Hoffmann-La Roche AG | $2,939 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-09-23 | Edwards Lifesciences Corporation | $38,267 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-09-23 | Edwards Lifesciences Corporation | $3,901 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-09-23 | Edwards Lifesciences Corporation | $1,900 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-09-22 | Regeneron Pharmaceuticals, Inc. | $1,550 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-09-21 | Genentech, Inc. | $2,011 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-09-20 | Edwards Lifesciences Corporation | $2,850 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-09-16 | E.R. Squibb & Sons, L.L.C. | $1,080 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph III registrational study in 1L HCC nivo monotherapy | 2021 |
| 2021-09-14 | Medtronic, Inc. | $2,110 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-09-13 | Genentech, Inc. | $1,682 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-09-13 | Edwards Lifesciences Corporation | $270 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-09-07 | E.R. Squibb & Sons, L.L.C. | $3,307 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph IIb 2L Bladder Registrational | 2021 |
| 2021-09-02 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $3,450 | Research payment | Cash or cash equivalent | SAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS | 2021 | |
| 2021-08-31 | Medtronic, Inc. | $12,000 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | SMART Trial | 2021 |
| 2021-08-26 | PFIZER INC. | $5,355 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2021 |
| 2021-08-26 | Intercept Pharmaceuticals, Inc. | $2,712 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-08-18 | Genentech, Inc. | $27 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2021 |
| 2021-08-12 | Edwards Lifesciences Corporation | $16,269 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-08-11 | Alexion Pharmaceuticals, Inc. | $1,900 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension | 2021 | |
| 2021-08-11 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2021 |
| 2021-08-05 | Intercept Pharmaceuticals, Inc. | $922 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-08-05 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-08-05 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-08-04 | Genentech, Inc. | $2,709 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2021 |
| 2021-08-04 | SK Life Science, Inc. | $2,544 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | 059566 | 2021 |
| 2021-08-03 | SK Life Science, Inc. | $33 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | 059566 | 2021 |
| 2021-08-02 | Genentech, Inc. | $950 | Research payment | Cash or cash equivalent | Drug | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2021 |
| 2021-07-29 | Intercept Pharmaceuticals, Inc. | $2,770 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-07-28 | Genentech, Inc. | $31,573 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2021 |
| 2021-07-28 | Novocure Inc. | $7,993 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2021 | |
| 2021-07-28 | Novocure Inc. | $6,788 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2021 | |
| 2021-07-16 | Novocure Inc. | $11,082 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2021 | |
| 2021-07-08 | Edwards Lifesciences Corporation | $75,687 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-07-08 | Edwards Lifesciences Corporation | $1,250 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-07-08 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-07-07 | ModernaTX, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2021 | |
| 2021-07-07 | ModernaTX, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2021 | |
| 2021-07-06 | F. Hoffmann-La Roche AG | $2,000 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-07-06 | Genentech, Inc. | $1,251 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-06-24 | Intercept Pharmaceuticals, Inc. | $5,950 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-06-21 | Edwards Lifesciences Corporation | $8,316 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2021 | |
| 2021-06-21 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2021 | |
| 2021-06-17 | Edwards Lifesciences Corporation | $6,669 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-06-14 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERJETA SAFETY STUDY IN NEO ADJUVANT BC | 2021 |
| 2021-06-10 | Regeneron Pharmaceuticals, Inc. | $5,500 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-06-10 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-06-10 | Regeneron Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2021 | |
| 2021-06-10 | Intercept Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-06-09 | Medtronic, Inc. | $1,550 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-06-08 | E.R. Squibb & Sons, L.L.C. | $675 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Nivo ipi vs Nivo in Stage IIIb c or IV Adjuvant Melanoma | 2021 |
| 2021-06-08 | Medtronic, Inc. | $574 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-06-07 | Edwards Lifesciences Corporation | $1,980 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-06-04 | Merck Sharp & Dohme LLC | $249,665 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2021 |
| 2021-06-03 | Intercept Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-05-28 | Edwards Lifesciences Corporation | $4,583 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-05-28 | Eli Lilly and Company | $1,670 | Research payment | Cash or cash equivalent | CYRAMZA Drug, Oncology | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO | 2021 |
| 2021-05-27 | Intercept Pharmaceuticals, Inc. | $3,780 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-05-27 | Chiesi USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KENGREAL Drug, CARDIOVASCULAR | 2021 | |
| 2021-05-27 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-05-27 | Bio-Rad Laboratories, Inc. | $18 | Debt forgiveness | Cash or cash equivalent | Liquichek Device, Controls | 2021 | |
| 2021-05-24 | Edwards Lifesciences Corporation | $1,550 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-05-24 | Johnson & Johnson Health Care Systems Inc. | $493 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-21 | E.R. Squibb & Sons, L.L.C. | $11,725 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Melanoma 2 3L IPI Progressors | 2021 |
| 2021-05-21 | Genentech, Inc. | $820 | Research payment | Cash or cash equivalent | Drug | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2021 |
| 2021-05-21 | ARRAY BIOPHARMA INC | $650 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2021 |
| 2021-05-17 | Sirtex Medical Inc | $135 | Research payment | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study | 2021 |
| 2021-05-12 | Sirtex Medical Inc | $4,715 | Research payment | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study | 2021 |
| 2021-05-10 | Novocure Inc. | $1,061 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2021 | |
| 2021-05-06 | Edwards Lifesciences Corporation | $6,054 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-05-06 | Intercept Pharmaceuticals, Inc. | $120 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-05-03 | Genentech, Inc. | $615 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-04-23 | Medtronic, Inc. | $2,164 | Long term medical supply or device loan | In-kind items and services | Emprint Device, Ablation | 2021 | |
| 2021-04-23 | Genentech, Inc. | $600 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2021 |
| 2021-04-22 | Amgen Inc. | $1,360 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2021 | |
| 2021-04-21 | ARRAY BIOPHARMA INC | $1,250 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2021 |
| 2021-04-16 | Takeda Pharmaceuticals U.S.A., Inc. | $2,220 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-04-15 | Intercept Pharmaceuticals, Inc. | $6,932 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-04-15 | Alexion Pharmaceuticals, Inc. | $2,936 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 | |
| 2021-04-15 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-04-05 | Edwards Lifesciences Corporation | $64,449 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-04-05 | Edwards Lifesciences Corporation | $22,990 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2021 | |
| 2021-03-30 | Genentech, Inc. | $3,335 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-03-30 | Genentech, Inc. | $1,865 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-03-27 | Genentech, Inc. | $2,120 | Research payment | Cash or cash equivalent | Drug | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-27 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Drug | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-27 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Drug | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-03-18 | Edwards Lifesciences Corporation | $25,315 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-03-18 | Edwards Lifesciences Corporation | $14,087 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-03-18 | Intercept Pharmaceuticals, Inc. | $3,695 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-03-16 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2021 |
| 2021-03-11 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-03-11 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-03-09 | CSL Behring | $604 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2021 |
| 2021-03-08 | Medtronic, Inc. | $4,969 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-03-06 | Genentech, Inc. | $8,550 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2021 |
| 2021-03-06 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2021 |
| 2021-03-05 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2021 |
| 2021-03-01 | Sirtex Medical Inc | $2,800 | Research payment | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study | 2021 |
| 2021-03-01 | Sirtex Medical Inc | $2,160 | Research payment | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study | 2021 |
| 2021-03-01 | Sirtex Medical Inc | $945 | Research payment | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study | 2021 |
| 2021-03-01 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-02-25 | Intercept Pharmaceuticals, Inc. | $8,635 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-02-23 | Genentech, Inc. | $3,990 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-23 | Genentech, Inc. | $167 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-19 | Genentech, Inc. | $1,157 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-19 | Genentech, Inc. | $1,157 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-19 | Genentech, Inc. | $280 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERJETA SAFETY STUDY IN NEO ADJUVANT BC | 2021 |
| 2021-02-18 | Edwards Lifesciences Corporation | $1,300 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2021 | |
| 2021-02-18 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-02-11 | E.R. Squibb & Sons, L.L.C. | $10,372 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Monotherapy | 2021 |
| 2021-02-11 | E.R. Squibb & Sons, L.L.C. | $2,325 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant HCC mono vs placebo | 2021 |
| 2021-02-09 | Medtronic, Inc. | $1,900 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-02-08 | E.R. Squibb & Sons, L.L.C. | $7,483 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2021 | |
| 2021-02-08 | E.R. Squibb & Sons, L.L.C. | $1,869 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2021 | |
| 2021-02-08 | F. Hoffmann-La Roche AG | $1,000 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2021 |
| 2021-02-04 | Intercept Pharmaceuticals, Inc. | $1,852 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-02-03 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Drug | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2021 |
| 2021-02-02 | E.R. Squibb & Sons, L.L.C. | $128,799 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2021 |
| 2021-02-02 | E.R. Squibb & Sons, L.L.C. | $16,405 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase II 1L Mel - IPI Combo | 2021 |
| 2021-02-02 | E.R. Squibb & Sons, L.L.C. | $12,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Stage III Unresectable NSCLC Combo | 2021 |
| 2021-02-02 | Genentech, Inc. | $1,655 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-02 | Genentech, Inc. | $606 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-02 | Genentech, Inc. | $167 | Research payment | Cash or cash equivalent | Drug | GDC0068 COMB W TAXOTERE OR FOLFOX | 2021 |
| 2021-02-01 | Genentech, Inc. | $2,842 | Research payment | Cash or cash equivalent | Drug | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2021 |
| 2021-01-28 | Edwards Lifesciences Corporation | $1,337 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-01-22 | Jenavalve Technology, Inc. | $242,056 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (8 payments) | Cash or cash equivalent | JenaValve Pericardial TAVR System Device, Cardiology | 2021 | |
| 2021-01-22 | Genentech, Inc. | $841 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-01-21 | Intercept Pharmaceuticals, Inc. | $39 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-01-20 | Partner Therapeutics, Inc. | $10,050 | Research payment | Cash or cash equivalent | LEUKINE Drug, Hematology/Oncology | iLEUK Pulm | 2021 |
| 2021-01-14 | Medtronic, Inc. | $12,551 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2021 |
| 2021-01-11 | Edwards Lifesciences Corporation | $1,337 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-01-08 | Takeda Pharmaceuticals U.S.A., Inc. | $280 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-01-06 | Genentech, Inc. | $6,500 | Research payment | Cash or cash equivalent | Drug | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-01-06 | Genentech, Inc. | $1,532 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-01-05 | SK Life Science, Inc. | $675 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | 1-FA7759 | 2021 |
| 2021-01-05 | SK Life Science, Inc. | $600 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | 1-FA7759 | 2021 |
| 2021-01-05 | SK Life Science, Inc. | $265 | Research payment | Cash or cash equivalent | XCOPRI Drug, Neurology | 1-FA7759 | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments